BCI Atlas

A grounded snapshot of Neuralink: what it is building, where it is, how big it is, and what is publicly known from primary sources.

Company — American

Neuralink (company brief)

BCI · invasive · intracortical · Neuralink

Neuralink is one of the highest-profile brain–computer interface (BCI) companies. It is building an implantable, wireless intracortical recording system and a surgical robot intended to place fine electrode “threads” into cortex. The company’s stated early medical focus is helping people with severe paralysis control digital devices.

This is a company brief: what can be supported by public sources, what is uncertain, and what to watch.

At a glance

What they are building (technical description)

Neuralink’s public descriptions point to a system with three major pieces:

  1. Implant (intracortical recording hardware)
  • A brain implant intended to record neural activity (and transmit data wirelessly to external devices).
  1. Surgical robot
  • A robotic system designed to insert electrode threads with high precision.
  1. Decoding/software layer
  • Software that maps recorded neural signals to control of a cursor and other device actions.

In plain terms: record spikes in motor-related cortex → decode intent → move a cursor.

What they’ve done recently (publicly reported)

First human implant (reported)

News reporting in early 2024 describes the first human implant and the beginning of human testing.

Trials + participant counts (reported)

Reuters reporting in mid‑2025 states Neuralink had begun clinical trials across multiple countries and that patients were using the system to control devices.

Production / automation goals (reported)

Money: revenue vs funding (what we can and can’t say)

Revenue

Neuralink is privately held; revenue is not publicly disclosed in a reliable, audited way. If you see revenue figures online, they are usually estimates.

Funding (reported)

Neuralink is best thought of as:

  • high-channel-count intracortical recording (aspirationally “high bandwidth”),
  • paired with a hardware + surgical-automation strategy,
  • pushing toward consumer-like usability (wireless, at-home use) but inside a very hard medical/regulatory environment.

What’s still unclear / key questions to watch

  1. Long-term reliability
  • Signal stability over months/years; electrode encapsulation; durability of threads; explant/replacement strategy.
  1. Surgical throughput + risk
  • Whether automation actually reduces time, cost, and complication rates at scale.
  1. True information throughput
  • “Channel count” is not the same as usable degrees-of-freedom. The key is stable decoding performance over time.
  1. Clinical indication pathway
  • Near-term: paralysis/cursor control is a plausible first product path.
  • Longer-term claims (speech, vision, broader neurological conditions) need careful evidence.

Notes on sourcing

I’m intentionally favoring primary/major reporting sources (e.g., Reuters) and official pages over scraped “startup list” aggregators. For private-company stats (employees, location), public directories and LinkedIn are imperfect but often the best available signals.